Merck's Keytruda Subcutaneous Injection Approved for Launch in China
nashnova research
On September 28, China's drug regulator approved Merck's subcutaneous formulation of Keytruda (pembrolizumab), cutting administration time from 30 minutes to as little as 1 minute — a convenience upgrade that could reshape how China's cancer patients access the world's top-selling PD-1 therapy.
How much faster is the subcutaneous shot?
The existing Keytruda formulation requires a 30-minute intravenous infusion.
The newly approved subcutaneous version: the every-3-week regimen finishes in under 1 minute; the every-6-week regimen in under 2 minutes.
In plain terms = patients go from "sit for half an hour on an IV drip" to "get a shot and leave," drastically cutting time spent in hospital.
Did the pivotal clinical data hold up?
Approval rests on the Phase III trial MK-3475A-D77 — a randomized, open-label study enrolling 378 patients with metastatic non-small-cell lung cancer.
The study set dual primary endpoints: ① area under the curve for pembrolizumab in the first dosing cycle (measuring total drug exposure); ② trough concentration at steady state (ensuring sustained therapeutic coverage).
Both endpoints were met. Merck announced these positive results in November 2024. This means → subcutaneous and IV delivery are comparable in efficacy and drug absorption — faster does not mean weaker.
What are the injection requirements?
The shot can be given in the thigh or abdomen, but must avoid the 5 cm zone around the navel.
Put simply = the procedure is straightforward, similar to a standard insulin injection — a profile that supports future rollout to community-level clinics.
What does this mean for Keytruda's commercial position in China?
Keytruda (pembrolizumab) is the world's highest-revenue PD-1 immunotherapy, but in China it faces intense competition from multiple domestic PD-1 rivals.
This means → the subcutaneous formulation's core edge is not a difference in efficacy but in administration convenience — shorter patient visits and less demand on hospital infusion resources.
This reflects Merck's strategy of using a formulation upgrade to defend Keytruda's market position in China, though whether it truly accelerates clinical adoption will require follow-up commercial data to confirm.
市场有风险，内容仅供研究参考，不构成投资建议。